Numerous clinical trials evaluate pemetrexed disodium across Early Phase 1 through Phase 4 studies for indications including non-small cell lung cancer, malignant pleural mesothelioma, stomach neoplasms, and colorectal carcinomas. Supported by academic and pharmaceutical sponsors, these studies encompass recruiting, completed, active not recruiting, and terminated recruitment statuses. Prominent research includes several clinical trials evaluating platinum-pemetrexed combination therapy in ALK-mutated metastatic NSCLC, folinic acid intervention for pemetrexed-induced neutropenia, and pemetrexed-based regimens paired with novel immunotherapies.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06096844 | RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2024-07-19 | PHASE3 |
| NCT04198766 | RECRUITING | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer |
Inhibrx Biosciences, Inc |
2019-12-10 | PHASE1; PHASE2 |
| NCT07642024 | RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-07-24 | PHASE2; PHASE3 |
| NCT06731907 | RECRUITING | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2025-03-30 | PHASE2 |
| NCT04165070 | RECRUITING | Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2019-12-19 | PHASE1; PHASE2 |
| NCT06788912 | RECRUITING | Lung Neoplasm Malignant |
Merck Sharp & Dohme LLC |
2025-03-20 | PHASE2 |
| NCT05789082 | RECRUITING | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2023-06-20 | PHASE1; PHASE2 |
| NCT07063745 | RECRUITING | Metastatic Non-small Cell Lung Cancer With MTAP Deletion |
Bristol-Myers Squibb |
2026-01-02 | PHASE2; PHASE3 |
| NCT07507188 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Yonsei University |
2026-04-06 | PHASE2 |
| NCT06109402 | NOT_YET_RECRUITING | Stage II-IIIB(N2) Non-small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2023-12-20 | PHASE2 |
| NCT07001618 | RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-11-17 | PHASE2 |
| NCT07709585 | NOT_YET_RECRUITING | Advanced Non-small Cell Lung Cancer (NSCLC); EGFR Exon 19 Deletion Mutation; EGFR Exon 21 Mutation; EGFR Exon 21 L858R Mutation |
Guangzhou University of Traditional Chinese Medicine |
2026-07-05 | PHASE2 |
| NCT06561386 | RECRUITING | Non-small Cell Lung Cancer |
Bristol-Myers Squibb |
2024-10-07 | PHASE3 |
| NCT07775040 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer |
Sichuan Cancer Hospital and Research Institute |
2026-08-20 | PHASE2 |
| NCT05719558 | RECRUITING | Advanced Solid Tumors |
Astellas Pharma Global Development, Inc. |
2023-03-13 | PHASE1 |
| NCT05067283 | RECRUITING | Advanced Solid Tumors |
Merck Sharp & Dohme LLC |
2021-12-17 | PHASE1 |
| NCT06745882 | RECRUITING | Non-small Cell Lung Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2025-06-13 | PHASE2 |
| NCT06607185 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor |
Eli Lilly and Company |
2024-10-21 | PHASE1 |
| NCT04665206 | RECRUITING | Solid Tumor, Adult; Mesothelioma; NSCLC |
Vivace Therapeutics, Inc |
2021-03-24 | PHASE1; PHASE2 |
| NCT05633667 | ACTIVE_NOT_RECRUITING | Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer |
Gilead Sciences |
2023-03-16 | PHASE2 |
| NCT03899155 | RECRUITING | Cancer |
Bristol-Myers Squibb |
2019-08-09 | PHASE2 |
| NCT05555732 | ACTIVE_NOT_RECRUITING | Metastatic Non Small Cell Lung Cancer |
Daiichi Sankyo |
2023-01-11 | PHASE3 |
| NCT06630416 | RECRUITING | Metastatic Bladder Urothelial Carcinoma; Metastatic Malignant Solid Neoplasm; Stage IV Bladder Cancer AJCC v8; MTAP Deletion |
Northwestern University |
2024-11-27 | PHASE2 |
| NCT06632327 | ACTIVE_NOT_RECRUITING | Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2024-12-11 | PHASE3 |
| NCT07608731 | NOT_YET_RECRUITING | Large B-cell Lymphoma; Central Nervous System Lymphoma |
Allison Winter |
2026-10 | PHASE1 |
| NCT07514793 | NOT_YET_RECRUITING | Mesothelioma |
Fudan University |
2026-04 | PHASE2 |
| NCT07098988 | RECRUITING | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor |
CatalYm GmbH |
2025-08-01 | PHASE2 |
| NCT07661173 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Anhui Provincial Cancer Hospital |
2026-06-06 | PHASE2 |
| NCT06996782 | RECRUITING | Advanced or Metastatic Non-small Cell Lung Cancer |
AstraZeneca |
2025-11-24 | PHASE1; PHASE2 |
| NCT06712316 | RECRUITING | Non-small Cell Lung Cancer |
BioNTech SE |
2025-01-07 | PHASE2; PHASE3 |
| NCT07100080 | RECRUITING | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2025-11-05 | PHASE2; PHASE3 |
| NCT07020221 | RECRUITING | Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS |
Verastem, Inc. |
2025-06-24 | PHASE1; PHASE2 |
| NCT06793215 | RECRUITING | Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer |
Hoffmann-La Roche |
2025-10-24 | PHASE3 |
| NCT06097728 | ACTIVE_NOT_RECRUITING | Unresectable Pleural Mesothelioma |
AstraZeneca |
2023-11-09 | PHASE3 |
| NCT07181499 | RECRUITING | NSCLC; Adjuvant Drug Therapy; EGFR |
Betta Pharmaceuticals Co., Ltd. |
2025-09 | PHASE2 |
| NCT01878617 | ACTIVE_NOT_RECRUITING | Medulloblastoma |
St. Jude Children's Research Hospital |
2013-06-23 | PHASE2 |
| NCT06057935 | RECRUITING | Malignant Peritoneal Mesothelioma; Peritoneal Mesothelioma; Mesothelioma; Mesothelioma, Malignant; Malignant Mesothelioma |
Memorial Sloan Kettering Cancer Center |
2023-09-21 | PHASE2 |
| NCT07020065 | RECRUITING | Metastatic NSCLC - Non-Small Cell Lung Cancer |
Swiss Cancer Institute |
2026-04-10 | PHASE2 |
| NCT07754123 | NOT_YET_RECRUITING | Advanced or Metastatic NSCLC |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2026-09-17 | PHASE3 |
| NCT07420439 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer Metastatic; Interstitial Lung Disease (ILD) |
Intergroupe Francophone de Cancerologie Thoracique |
2026-09-15 | PHASE2 |
| NCT06281964 | ENROLLING_BY_INVITATION | Non-Small-Cell Lung Cancer |
Avistone Biotechnology Co., Ltd. |
2023-12-01 | PHASE3 |
| NCT06459180 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
Merck Sharp & Dohme LLC |
2024-07-24 | PHASE3 |
| NCT05502237 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Gilead Sciences |
2022-10-12 | PHASE3 |
| NCT06268210 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Yonsei University |
2022-02-07 | PHASE2 |
| NCT06861218 | NOT_YET_RECRUITING | Leptomeningeal Metastases |
Zhejiang Cancer Hospital |
2025-04 | PHASE2 |
| NCT07128303 | RECRUITING | Advanced Solid Tumor |
Gilead Sciences |
2025-08-28 | PHASE1 |
| NCT06093503 | WITHDRAWN | Non-Small Cell Lung Cancer |
AbbVie |
2024-05-31 | PHASE3 |
| NCT07383116 | NOT_YET_RECRUITING | Non Squamous Non-small Cell Lung Cancer |
Shanghai Huaota Biopharmaceutical Co., Ltd. |
2026-01-15 | PHASE3 |
| NCT06441045 | NOT_YET_RECRUITING | Leptomeningeal Metastasis |
Fujian Cancer Hospital |
2024-10-01 | PHASE2 |
| NCT06908993 | RECRUITING | Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation |
Intergroupe Francophone de Cancerologie Thoracique |
2025-12-09 | PHASE3 |
| NCT05681195 | RECRUITING | Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Relapsed Cancer; Refractory Cancer |
Baptist Health South Florida |
2024-04-25 | PHASE2 |
| NCT05764928 | NOT_YET_RECRUITING | Nonsquamous Nonsmall Cell Neoplasm of Lung |
Rgene Corporation |
2026-12-01 | PHASE1; PHASE2 |
| NCT05791097 | WITHDRAWN | Non-small Cell Lung Cancer (NSCLC) |
Novartis Pharmaceuticals |
2023-07-28 | PHASE3 |
| NCT07178795 | RECRUITING | Non-squamous Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-09-29 | PHASE3 |
| NCT06956001 | RECRUITING | EGFR; NSCLC (Advanced Non-small Cell Lung Cancer) |
Allist Pharmaceuticals, Inc. |
2024-11-19 | PHASE3 |
| NCT04605770 | RECRUITING | Sarcoma,Soft Tissue |
Yonsei University |
2020-12-22 | PHASE2 |
| NCT06901817 | RECRUITING | Leptomeningeal Metastasis |
Shanghai Cancer Hospital, China |
2025-03-01 | PHASE2 |
| NCT07154368 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Guangzhou JOYO Pharma Co., Ltd |
2025-09-23 | PHASE3 |
| NCT06561685 | RECRUITING | Metastatic Solid Tumor; Advanced Solid Tumor; Non-small Cell Lung Cancer; SMARCA4-Deficient Tumor |
Eli Lilly and Company |
2024-09-19 | PHASE1 |
| NCT05335941 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma; Metastatic Cancer |
M.D. Anderson Cancer Center |
2023-06-13 | PHASE2 |
| NCT03233139 | ACTIVE_NOT_RECRUITING | Advanced Malignancies |
Regeneron Pharmaceuticals |
2017-06-21 | PHASE1 |
| NCT04837716 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2021-03-18 | PHASE1 |
| NCT04253964 | RECRUITING | Nonsmall Cell Lung Cancer; Performance Status |
Wake Forest University Health Sciences |
2020-07-01 | PHASE2 |
| NCT05487391 | RECRUITING | Carcinoma, Non-Small-Cell Lung |
Qilu Pharmaceutical Co., Ltd. |
2022-12-08 | PHASE3 |
| NCT06784791 | RECRUITING | Lung Cancer (NSCLC) |
University Hospital, Essen |
2024-11-06 | PHASE2 |
| NCT00715611 | ACTIVE_NOT_RECRUITING | Mesothelioma |
Memorial Sloan Kettering Cancer Center |
2008-10-11 | PHASE2 |
| NCT06564844 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2024-10-15 | PHASE3 |
| NCT05198830 | ACTIVE_NOT_RECRUITING | Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2022-12-15 | PHASE2 |
| NCT05096663 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-03-15 | PHASE2; PHASE3 |
| NCT06726265 | ACTIVE_NOT_RECRUITING | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Immutep S.A.S. |
2025-03-21 | PHASE3 |
| NCT07070440 | RECRUITING | Non Small Cell Lung Cancer |
Dizal Pharmaceuticals |
2025-07-16 | PHASE1; PHASE2 |
| NCT06074588 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer (NSCLC) |
Merck Sharp & Dohme LLC |
2023-11-12 | PHASE3 |
| NCT04410796 | RECRUITING | Metastatic Non-small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2020-05-28 | PHASE2 |
| NCT06969612 | RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Peking University Cancer Hospital & Institute |
2025-05-15 | PHASE1 |
| NCT05715229 | RECRUITING | Carcinoma, Non-Small-Cell Lung |
Hackensack Meridian Health |
2023-09-29 | PHASE2 |
| NCT02817633 | ACTIVE_NOT_RECRUITING | Neoplasms |
Tesaro, Inc. |
2016-07-08 | PHASE1 |
| NCT05443126 | RECRUITING | NSCLC |
Ellipses Pharma |
2022-09-30 | PHASE1; PHASE2 |
| NCT06946797 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2025-09-19 | PHASE2 |
| NCT06462092 | RECRUITING | Leptomeningeal Metastases |
Guangzhou Medical University |
2026-01-01 | PHASE1; PHASE2 |
| NCT02609776 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Cancer |
Janssen Research & Development, LLC |
2016-05-24 | PHASE1 |
| NCT07381829 | RECRUITING | Advanced Solid Tumor Cancer |
HC Biopharma Inc. |
2025-10-27 | PHASE1 |
| NCT06809530 | ACTIVE_NOT_RECRUITING | Leptomeningeal Metastasis; Pemetrexed; PD-1 Inhibitor; CTLA4; Solid Tumors |
Guangzhou Medical University |
2025-03-17 | PHASE1; PHASE2 |
| NCT03786692 | ACTIVE_NOT_RECRUITING | Non-Small Cell Carcinoma of Lung, TNM Stage 4 |
Fox Chase Cancer Center |
2019-09-04 | PHASE2 |
| NCT05456256 | RECRUITING | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung |
Lantern Pharma Inc. |
2023-03-01 | PHASE2 |
| NCT06943820 | RECRUITING | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Adenocarcinoma; Advanced Solid Tumors |
Akeso |
2025-05-21 | PHASE1; PHASE2 |
| NCT06652048 | RECRUITING | Non-Small Cell Lung Cancer |
Jialei Wang |
2024-10-01 | PHASE2 |
| NCT07122687 | RECRUITING | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer |
Innovent Biologics (Suzhou) Co. Ltd. |
2025-08-26 | PHASE2 |
| NCT06704620 | NOT_YET_RECRUITING | Advanced and Metastatic NSCLC |
Tianjin Medical University Cancer Institute and Hospital |
2024-12 | PHASE3 |
| NCT04162015 | ACTIVE_NOT_RECRUITING | Malignant Pleural Mesothelioma |
Memorial Sloan Kettering Cancer Center |
2019-11-12 | PHASE1 |
| NCT04129502 | ACTIVE_NOT_RECRUITING | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Takeda |
2020-01-10 | PHASE3 |
| NCT06447662 | ACTIVE_NOT_RECRUITING | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-06-27 | PHASE1 |
| NCT04991025 | RECRUITING | Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III |
Memorial Sloan Kettering Cancer Center |
2022-10-19 | PHASE2 |
| NCT05116462 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Innovent Biologics (Suzhou) Co. Ltd. |
2024-03-15 | PHASE3 |
| NCT06762080 | ACTIVE_NOT_RECRUITING | Leptomeningeal Metastasis |
Guangzhou Medical University |
2025-03-07 | PHASE1; PHASE2 |
| NCT06883630 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
RemeGen Co., Ltd. |
2025-03-13 | PHASE1 |
| NCT06687369 | RECRUITING | Non Squamous Non Small Cell Lung Cancer |
mAbxience Research S.L. |
2024-12-30 | PHASE3 |
| NCT04339218 | RECRUITING | Lung Adenocarcinoma; Cryotherapy Effect |
Institut Bergonié |
2020-08-28 | PHASE3 |
| NCT06161441 | ACTIVE_NOT_RECRUITING | Resectable Non-small Cell Lung Cancer |
Regeneron Pharmaceuticals |
2024-07-16 | PHASE2 |
| NCT04966663 | RECRUITING | Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA |
University Health Network, Toronto |
2022-03-28 | PHASE2 |
| NCT06382116 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-05-22 | PHASE3 |
| NCT04585490 | RECRUITING | Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc |
Maximilian Diehn |
2021-08-25 | PHASE3 |
| NCT06462222 | ACTIVE_NOT_RECRUITING | Leptomeningeal Metastasis |
Guangzhou Medical University |
2024-06-30 | PHASE1; PHASE2 |
| NCT06405230 | TERMINATED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2025-10-10 | PHASE1; PHASE2 |
| NCT06505837 | ACTIVE_NOT_RECRUITING | Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer |
Shanghai Junshi Bioscience Co., Ltd. |
2024-07-11 | PHASE3 |
| NCT06318286 | ACTIVE_NOT_RECRUITING | Malignant Pleural Mesothelioma |
Hyogo Medical University |
2024-03-13 | PHASE2 |
| NCT05298423 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2022-05-03 | PHASE3 |
| NCT05048797 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
AstraZeneca |
2021-10-28 | PHASE3 |
| NCT04335292 | RECRUITING | Non-Small Cell Lung Cancer |
Mark Vincent |
2021-01-06 | PHASE2 |
| NCT05017012 | COMPLETED | Advanced or Metastatic Solid Tumors |
Merck Sharp & Dohme LLC |
2021-09-21 | PHASE1 |
| NCT06704724 | TERMINATED | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-12-10 | PHASE1 |
| NCT07365410 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer (NSCLC); Brain Metastases; Furmonertinib; EGFR Mutation |
Tianjin Medical University Cancer Institute and Hospital |
2026-01 | PHASE2 |
| NCT04638582 | TERMINATED | Lung Cancer, Nonsmall Cell |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2022-08-28 | PHASE2 |
| NCT06688656 | NOT_YET_RECRUITING | Lung Cancer |
Shanghai Chest Hospital |
2025-03-31 | PHASE2 |
| NCT06812871 | COMPLETED | Non-small Cell Lung Cancer Metastatic |
Sun Yat-sen University |
2024-01-01 | PHASE2 |
| NCT05689671 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer Metastatic |
Nikolaj Frost MD |
2023-12-06 | PHASE4 |
| NCT06809517 | RECRUITING | Leptomeningeal Metastasis; Intrathecal Drug Delivery |
Guangzhou Medical University |
2025-03-18 | PHASE1; PHASE2 |
| NCT05117476 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor; NSCLC |
Cullinan Therapeutics Inc. |
2021-10-29 | PHASE1 |
| NCT04147351 | COMPLETED | NSCLC Stage IIIB~IV |
National Taiwan University Hospital |
2020-04-10 | PHASE2 |
| NCT05501665 | RECRUITING | Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2023-05-09 | PHASE1; PHASE2 |
| NCT05668988 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Dizal Pharmaceuticals |
2022-12-13 | PHASE3 |
| NCT03623776 | WITHDRAWN | Efficacy and Safety |
Sun Yat-sen University |
2019-02-01 | PHASE2 |
| NCT06713057 | NOT_YET_RECRUITING | Locally Advanced Thyroid Gland Carcinoma; Thyroid Cancer |
West China Hospital |
2024-12-01 | PHASE2 |
| NCT06659042 | RECRUITING | Lung Cancer, Non-Small Cell |
Shanghai Chest Hospital |
2024-11-20 | PHASE2 |
| NCT05136677 | COMPLETED | Mesothelioma, Malignant |
Bristol-Myers Squibb |
2022-01-25 | PHASE2 |
| NCT04695925 | ACTIVE_NOT_RECRUITING | Non-small Cell Carcinoma; EGFR Gene Mutation |
Li Zhang, MD |
2021-03-29 | PHASE3 |
| NCT05664971 | COMPLETED | Advanced Lung Cancer |
Shanghai Junshi Bioscience Co., Ltd. |
2023-02-09 | PHASE1; PHASE2 |
| NCT04649385 | COMPLETED | Advanced Solid Tumor |
BeiGene |
2021-03-04 | PHASE1 |
| NCT03520686 | TERMINATED | Non Small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-05-18 | PHASE3 |
| NCT06455046 | UNKNOWN | Cervical Cancer Recurrent |
Fujian Cancer Hospital |
2023-10-11 | PHASE2 |
| NCT05754853 | RECRUITING | Advanced or Metastatic Urothelium Cancer |
Shanghai Miracogen Inc. |
2023-04-06 | PHASE3 |
| NCT03564691 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2018-07-11 | PHASE1 |
| NCT05430802 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Tang-Du Hospital |
2022-02-24 | PHASE2 |
| NCT06537297 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2024-09-30 | PHASE2 |
| NCT04717375 | TERMINATED | Cancer; Neoplasm |
Sanofi |
2021-04-11 | PHASE1; PHASE2 |
| NCT05794477 | UNKNOWN | Advanced Solid Tumor |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2023-04-28 | PHASE1; PHASE2 |
| NCT05930665 | UNKNOWN | Pleural Mesothelioma |
Sun Yat-sen University |
2023-11-01 | PHASE2 |
| NCT05465733 | UNKNOWN | Non-Small-Cell Lung |
First Affiliated Hospital Xi'an Jiaotong University |
2022-08-01 | PHASE2 |
| NCT04530227 | UNKNOWN | Early Stage Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2020-09-25 | PHASE2 |
| NCT03918278 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2019-06-19 | PHASE1 |
| NCT03944772 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
AstraZeneca |
2019-06-25 | PHASE2 |
| NCT05255302 | RECRUITING | Metastatic NSCLC |
Intergroupe Francophone de Cancerologie Thoracique |
2022-05-02 | PHASE2; PHASE3 |
| NCT03088540 | COMPLETED | Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer |
Regeneron Pharmaceuticals |
2017-05-29 | PHASE3 |
| NCT06396065 | ACTIVE_NOT_RECRUITING | Non-Squamous Non-small Cell Lung Cancer |
Summit Therapeutics |
2023-05-04 | PHASE3 |
| NCT06643000 | RECRUITING | Non-small Cell Lung Cancer; Leptomeningeal Metastasis; EGFR Gene Mutation |
Henan Cancer Hospital |
2024-12-20 | |
| NCT04832854 | TERMINATED | Non-Small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2021-04-23 | PHASE2 |
| NCT03242915 | COMPLETED | Non-small Cell Lung Cancer |
University of Michigan Rogel Cancer Center |
2017-10-03 | PHASE2 |
| NCT04222972 | TERMINATED | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue |
Hoffmann-La Roche |
2020-07-24 | PHASE3 |
| NCT05810350 | UNKNOWN | Non-small Cell Lung Cancer |
Three Gorges Hospital of Chongqing University |
2023-01-01 | PHASE2 |
| NCT06110663 | UNKNOWN | Non-Small Cell Lung Cancer |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2023-12-30 | PHASE3 |
| NCT03875144 | SUSPENDED | Peritoneal Mesothelioma; Peritoneal Carcinomatosis |
Institut du Cancer de Montpellier - Val d'Aurelle |
2020-09-10 | PHASE2 |
| NCT05577702 | COMPLETED | Non Small Cell Lung Cancer |
BeiGene |
2023-03-08 | PHASE2 |
| NCT04856176 | TERMINATED | Advanced Lung Non-Small Cell Carcinoma; Non-Small Cell Carcinoma of Lung, TNM Stage 4 |
Tufts Medical Center |
2022-01-03 | PHASE2 |
| NCT03846310 | COMPLETED | Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer; Nonsquamous Nonsmall Cell Neoplasm of Lung; Sensitizing EGFR Gene Mutation |
Arcus Biosciences, Inc. |
2019-04-01 | PHASE1 |
| NCT02794571 | COMPLETED | Advanced/Metastatic Tumors |
Genentech, Inc. |
2016-05-23 | PHASE1 |
| NCT04287894 | TERMINATED | Stage III NSCLC |
The Netherlands Cancer Institute |
2018-12-28 | PHASE1 |
| NCT01656551 | UNKNOWN | Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB |
National Cancer Institute, Naples |
2012-08 | PHASE3 |
| NCT04765059 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2021-09-12 | PHASE3 |
| NCT05741021 | UNKNOWN | Non-small Cell Lung Cancer; NSCLC; PD-1 |
Shandong New Time Pharmaceutical Co., LTD |
2023-03-01 | PHASE2 |
| NCT02784171 | COMPLETED | Mesothelioma |
Canadian Cancer Trials Group |
2016-11-11 | PHASE2; PHASE3 |
| NCT05911308 | TERMINATED | Non-Small Cell Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2024-04-01 | PHASE1 |
| NCT05756972 | ACTIVE_NOT_RECRUITING | NSCLC |
Biotheus Inc. |
2023-06-26 | PHASE2 |
| NCT06020989 | UNKNOWN | Non Small Cell Lung Cancer |
Yonsei University |
2023-09 | PHASE2 |
| NCT05299125 | COMPLETED | Metastatic Non-small Cell Lung Cancers |
Latin American Cooperative Oncology Group |
2023-05-24 | PHASE2 |
| NCT05746481 | TERMINATED | Non-small Cell Lung Cancer |
Liza Villaruz, MD |
2023-08-10 | PHASE2 |
| NCT06094296 | TERMINATED | NSCLC |
Bristol-Myers Squibb |
2023-11-27 | PHASE2 |
| NCT04047862 | COMPLETED | Locally Advanced and Metastatic Solid Tumors |
BeiGene |
2019-08-15 | PHASE1 |
| NCT04367311 | ACTIVE_NOT_RECRUITING | Lung Cancer; NSCLC |
Nasser Hanna |
2020-05-22 | PHASE2 |
| NCT06315686 | UNKNOWN | NSCLC |
Jiangsu Province Nanjing Brain Hospital |
2022-09-29 | PHASE2 |
| NCT04970043 | UNKNOWN | Lung Cancer Stage II |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2021-07-31 | |
| NCT02964013 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2016-12-13 | PHASE1 |
| NCT05132985 | NOT_YET_RECRUITING | NSCLC; EGF-R Positive Non-Small Cell Lung Cancer |
Liaoning Cancer Hospital & Institute |
2022-01-01 | PHASE2 |
| NCT04967417 | COMPLETED | Non-small Cell Lung Cancer |
Samsung Medical Center |
2022-05-26 | PHASE2 |
| NCT04619797 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2020-12-15 | PHASE2; PHASE3 |
| NCT05298176 | COMPLETED | Non-Small Cell Lung Cancer |
Amsterdam UMC, location VUmc |
2022-01-04 | PHASE2 |
| NCT04524689 | TERMINATED | Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) |
Sanofi |
2020-10-26 | PHASE2 |
| NCT05104788 | RECRUITING | Non-Small Cell Lung Cancer |
Peking University Cancer Hospital & Institute |
2021-10-25 | PHASE2 |
| NCT06378892 | Recruiting | Non Small Cell Lung Cancer Metastatic|ALK Gene Mutation |
Centro di Riferimento Oncologico - Aviano |
2024-03-15 | Phase 2 |
| NCT05611879 | UNKNOWN | NSCLC, Stage III |
Beijing Tsinghua Chang Gung Hospital |
2023-03-12 | PHASE2 |
| NCT05267366 | UNKNOWN | PFS; OS |
Qingdao Central Hospital |
2022-02-01 | PHASE2 |
| NCT04683965 | UNKNOWN | Colorectal Neoplasms |
The First Affiliated Hospital with Nanjing Medical University |
2021-01-01 | PHASE2 |
| NCT03380468 | UNKNOWN | Lung Neoplasms |
Fudan University |
2018-01-01 | PHASE2; PHASE3 |
| NCT06010277 | UNKNOWN | NSCLC; Mesothelioma; Thymoma |
Amphia Hospital |
2023-02-06 | PHASE4 |
| NCT05386888 | COMPLETED | NSCLC, Stage III |
Genfleet Therapeutics (Shanghai) Inc. |
2022-09-09 | PHASE2 |
| NCT04786964 | TERMINATED | Metastatic Non-squamous Non Small Cell Lung Cancer |
Checkpoint Therapeutics, Inc. |
2021-12-08 | PHASE3 |
| NCT03137771 | ACTIVE_NOT_RECRUITING | Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer |
NRG Oncology |
2017-04-07 | PHASE2 |
| NCT04205812 | COMPLETED | Metastatic Squamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer |
Incyte Corporation |
2020-09-11 | PHASE3 |
| NCT05394233 | UNKNOWN | Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation |
Sichuan Cancer Hospital and Research Institute |
2022-06-01 | PHASE2 |
| NCT05346952 | UNKNOWN | Advanced Non-squamous Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2022-01-25 | PHASE3 |
| NCT01951482 | COMPLETED | Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab |
Sun Yat-sen University |
2016-01 | PHASE3 |
| NCT04956146 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
The First Affiliated Hospital with Nanjing Medical University |
2022-02-02 | PHASE2 |
| NCT05011487 | RECRUITING | Non-Small Cell Lung Cancer |
Sun Yat-sen University |
2021-08-13 | PHASE2 |
| NCT04379635 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer |
BeiGene |
2020-05-29 | PHASE3 |
| NCT03829319 | COMPLETED | Nonsquamous Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2019-03-25 | PHASE3 |
| NCT04697628 | COMPLETED | Cervical Cancer |
Seagen, a wholly owned subsidiary of Pfizer |
2021-02-22 | PHASE3 |
| NCT03866980 | TERMINATED | Lung Cancer Non-small Cell Stage IV |
Akeso |
2018-11-27 | PHASE3 |
| NCT05459441 | UNKNOWN | Glioma; Brain Metastases |
Shanghai Pudong Hospital |
2022-01-01 | EARLY_PHASE1 |
| NCT04964960 | TERMINATED | Lung Cancer; Lung Cancer Metastatic; Brain Cancer; Cancer |
John L. Villano, MD, PhD |
2022-05-19 | PHASE2 |
| NCT03319537 | TERMINATED | Mesothelioma |
Memorial Sloan Kettering Cancer Center |
2017-10-05 | PHASE1; PHASE2 |
| NCT04846452 | UNKNOWN | Metastatic NSCLC; Recurrent NSCLC; Advanced Non-Small Cell Squamous Lung Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-06-01 | PHASE2 |
| NCT04194944 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2020-02-17 | PHASE3 |
| NCT04396457 | UNKNOWN | Non-squamous Non-small-cell Lung Cancer; Cancer, Lung |
National Hospital Organization Nagoya Medical Center |
2020-05-25 | PHASE2 |
| NCT04107103 | COMPLETED | SCCHN |
AHS Cancer Control Alberta |
2020-03-19 | PHASE2 |
| NCT04956692 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2021-08-05 | PHASE3 |
| NCT04083066 | UNKNOWN | Primary Central Nervous System Lymphoma |
Mingzhi Zhang |
2019-09-05 | PHASE4 |
| NCT05215951 | TERMINATED | Lung Cancer |
AstraZeneca |
2022-01-19 | PHASE2 |
| NCT04846634 | NOT_YET_RECRUITING | Resectable Locally Advanced Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08 | PHASE2 |
| NCT03840902 | TERMINATED | Non-small Cell Lung Cancer |
EMD Serono Research & Development Institute, Inc. |
2019-04-16 | PHASE2 |
| NCT04194203 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Hoffmann-La Roche |
2020-04-09 | PHASE3 |
| NCT06010277 | Recruiting | NSCLC|Mesothelioma|Thymoma |
Amphia Hospital|Albert Schweitzer Hospital |
2023-02-06 | Phase 4 |
| NCT02120807 | COMPLETED | Stage IV Lung Adenocarcinoma |
Memorial Sloan Kettering Cancer Center |
2014-04-15 | PHASE1 |
| NCT03515837 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2018-06-29 | PHASE3 |
| NCT02535312 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm |
National Cancer Institute (NCI) |
2016-03-08 | PHASE1; PHASE2 |
| NCT03574402 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Guangdong Association of Clinical Trials |
2018-07-09 | PHASE2 |
| NCT03003962 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Carcinoma NSCLC |
AstraZeneca |
2017-01-02 | PHASE3 |
| NCT03228537 | ACTIVE_NOT_RECRUITING | Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7; Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7; Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7; Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7; Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7 |
National Cancer Institute (NCI) |
2018-07-16 | PHASE1 |
| NCT04500717 | UNKNOWN | Non Small Cell Lung Cancer |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2020-10 | PHASE3 |
| NCT04422392 | TERMINATED | Non Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2020-07-13 | PHASE2 |
| NCT02709512 | COMPLETED | Mesothelioma |
Polaris Group |
2017-08-01 | PHASE2; PHASE3 |
| NCT03513666 | COMPLETED | NSCLC |
Shanghai Junshi Bioscience Co., Ltd. |
2018-04-09 | PHASE2 |
| NCT04022876 | TERMINATED | Non Small Cell Lung Cancer; Small-cell Lung Cancer |
Aileron Therapeutics, Inc. |
2019-09-03 | PHASE1 |
| NCT04861948 | TERMINATED | Solid Tumors; Lung Adenocarcinoma; Osteosarcoma |
Innovent Biologics (Suzhou) Co. Ltd. |
2021-05-25 | PHASE1 |
| NCT03838848 | TERMINATED | Stage IV Non-small Cell Lung Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2019-05-05 | PHASE2 |
| NCT03023319 | COMPLETED | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Bladder Cancer; Ovarian Cancer; Peritoneal Cancer; Thymoma; Thymus Cancer; Uterine Cervical Cancer |
Nagla Abdel Karim |
2019-12-10 | PHASE1 |
| NCT04372927 | TERMINATED | Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8 |
University of Washington |
2021-12-10 | PHASE2 |
| NCT04405674 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Chest Hospital |
2020-07-15 | PHASE2 |
| NCT04203485 | UNKNOWN | PD-L1 Positive Non-small Cell Lung Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-15 | PHASE3 |
| NCT03526900 | COMPLETED | Non-small Cell Lung Cancer Stage IV |
Spanish Lung Cancer Group |
2018-07-07 | PHASE2 |
| NCT04971187 | TERMINATED | Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Squamous Non-Small Cell Carcinoma |
M.D. Anderson Cancer Center |
2021-06-30 | PHASE2 |
| NCT02864251 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Bristol-Myers Squibb |
2017-03-17 | PHASE3 |
| NCT03863483 | UNKNOWN | Nonsquamous Non-Small Cell Lung Cancer |
Xin-Hua Xu |
2019-03-26 | PHASE2 |
| NCT04706949 | UNKNOWN | Lung Cancer, Non-small Cell |
Fudan University |
2020-12-07 | PHASE2 |
| NCT04470076 | UNKNOWN | Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2020-07-10 | PHASE2 |
| NCT03713944 | TERMINATED | NSCLC Stage IV; NSCLC, Recurrent |
Nasser Hanna |
2018-11-15 | PHASE2 |
| NCT02977169 | UNKNOWN | Non-small Cell Lung Cancer Stage IIIA; Radiotherapy |
Shanghai Chest Hospital |
2016-11 | PHASE2 |
| NCT04265534 | TERMINATED | Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene Mutation |
Calithera Biosciences, Inc |
2020-07-24 | PHASE2 |
| NCT03843853 | WITHDRAWN | Colorectal Neoplasms |
The First Affiliated Hospital with Nanjing Medical University |
2019-05-01 | PHASE2 |
| NCT04943627 | WITHDRAWN | Advanced Cancer; Metastatic Cervical Cancer |
Agenus Inc. |
2021-08-02 | PHASE3 |
| NCT04042558 | COMPLETED | NSCLC Stage IIIB; NSCLC Stage IV; EGFR Gene Mutation; ALK Gene Rearrangement Positive; ROS1 Gene Mutation |
Centre Francois Baclesse |
2019-09-26 | PHASE2 |
| NCT02743923 | UNKNOWN | Carcinoma, Non-Small Cell Lung |
The Netherlands Cancer Institute |
2016-04 | PHASE3 |
| NCT03809637 | COMPLETED | Sarcoma |
Yonsei University |
2017-01-10 | PHASE2 |
| NCT04470674 | WITHDRAWN | Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation |
Shirish M Gadgeel |
2021-04-06 | PHASE2 |
| NCT04439890 | UNKNOWN | Advanced Non-squamous Cell Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-08-08 | PHASE3 |
| NCT03987867 | UNKNOWN | Non-small Cell Lung Cancer; First-line Treatment |
Tianjin Medical University Cancer Institute and Hospital |
2019-06-01 | PHASE1 |
| NCT03655821 | TERMINATED | Non Small Cell Lung Cancer; Mesothelioma |
Radboud University Medical Center |
2019-02-01 | PHASE4 |
| NCT03177291 | COMPLETED | Lung Cancer; Non Small Cell Lung Cancer; Advanced Cancer; Metastatic Lung Cancer; Squamous Cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung |
H. Lee Moffitt Cancer Center and Research Institute |
2017-09-26 | PHASE1 |
| NCT02439450 | COMPLETED | Non-small Cell Lung Cancer |
Heat Biologics |
2015-04-15 | PHASE1; PHASE2 |
| NCT02710396 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Columbia University |
2016-05-31 | PHASE2 |
| NCT03562871 | COMPLETED | NSCLC |
IO Biotech |
2018-08-22 | PHASE1; PHASE2 |
| NCT02654587 | TERMINATED | Non Small Cell Lung Cancer |
OSE Immunotherapeutics |
2016-02-12 | PHASE3 |
| NCT03775486 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer NSCLC |
AstraZeneca |
2018-12-21 | PHASE2 |
| NCT03366766 | TERMINATED | Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-12-20 | PHASE2 |
| NCT03062800 | UNKNOWN | Advanced Nsclc |
Qilu Hospital of Shandong University |
2016-12 | PHASE2 |
| NCT02725918 | UNKNOWN | Non-small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2016-04-01 | PHASE2 |
| NCT02001168 | UNKNOWN | Non-small Cell Lung Cancer |
Xinjiang Medical University |
2013-10 | PHASE3 |
| NCT02862457 | COMPLETED | Neoplasms; Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2016-08-23 | PHASE1 |
| NCT02076477 | UNKNOWN | Oligo-metastatic Stage IV Non-small Cell Lung Cancer |
Sichuan Cancer Hospital and Research Institute |
2014-01 | PHASE3 |
| NCT03655834 | COMPLETED | Non Small Cell Lung Cancer; Mesothelioma |
Radboud University Medical Center |
2019-02-01 | PHASE4 |
| NCT02899299 | COMPLETED | Mesothelioma |
Bristol-Myers Squibb |
2016-11-29 | PHASE3 |
| NCT02535325 | COMPLETED | Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Adenocarcinoma AJCC v7; Stage III Lung Large Cell Carcinoma AJCC v7; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Adenocarcinoma AJCC v7; Stage IIIA Lung Large Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Adenocarcinoma AJCC v7; Stage IIIB Lung Large Cell Carcinoma AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Lung Adenocarcinoma AJCC v7; Stage IV Lung Large Cell Carcinoma AJCC v7; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2015-09-30 | PHASE1 |
| NCT03792503 | WITHDRAWN | Advanced Non-squamous Non-small-cell Lung Cancer |
Xinqiao Hospital of Chongqing |
2019-02 | PHASE4 |
| NCT03498222 | WITHDRAWN | Carcinoma, Non-Small-Cell Lung |
Queen Mary University of London |
2018-06-01 | PHASE1 |
| NCT03663205 | COMPLETED | Non-Small Cell Lung Cancer |
BeiGene |
2018-07-23 | PHASE3 |
| NCT03647956 | UNKNOWN | NSCLC Stage IIIB; NSCLC Stage IV; EGFR Activating Mutation |
The University of Hong Kong |
2018-10-01 | PHASE2 |
| NCT03628521 | UNKNOWN | Lung Cancer; Advanced Stage |
Shanghai Chest Hospital |
2018-07-20 | PHASE1 |
| NCT02693717 | TERMINATED | Metastatic Urothelial Carcinoma |
M.D. Anderson Cancer Center |
2017-05-09 | PHASE2 |
| NCT02777788 | UNKNOWN | Cancer |
Shanghai University of Traditional Chinese Medicine |
2014-09 | PHASE2; PHASE3 |
| NCT03193788 | UNKNOWN | Bladder Cancer; Ureter Cancer; Transitional Cell Carcinoma |
Asan Medical Center |
2017-01 | PHASE3 |
| NCT03058094 | WITHDRAWN | NSCLC |
Hangzhou ACEA Pharmaceutical Research Co., Ltd. |
2018-12 | PHASE3 |
| NCT02383212 | COMPLETED | Advanced Cancer; Advanced Malignancies |
Regeneron Pharmaceuticals |
2015-02-02 | PHASE1 |
| NCT03607539 | COMPLETED | Lung Neoplasms |
Innovent Biologics (Suzhou) Co. Ltd. |
2018-08-23 | PHASE3 |
| NCT02264990 | COMPLETED | Non-squamous Non-small Cell Lung Cancer |
AbbVie |
2014-09-30 | PHASE3 |
| NCT03269162 | UNKNOWN | NSCLC |
lihegen |
2016-09-30 | PHASE3 |
| NCT03351842 | RECRUITING | Chemotherapy, Adjuvant; Lung Adenocarcinoma, Stage I; Treatment; Histological Type of Neoplasm |
Shanghai Pulmonary Hospital, Shanghai, China |
2017-09-01 | PHASE2 |
| NCT02603003 | COMPLETED | Non-small Cell Lung Cancer(NSCLC) |
Shanghai University of Traditional Chinese Medicine |
2015-06 | PHASE1 |
| NCT03215706 | COMPLETED | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2017-08-24 | PHASE3 |
| NCT02657434 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2016-04-30 | PHASE3 |
| NCT02624700 | TERMINATED | Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer |
Virginia Commonwealth University |
2016-01-28 | PHASE2 |
| NCT03489616 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Shandong Cancer Hospital and Institute |
2018-01-15 | |
| NCT02886195 | UNKNOWN | EGFR Gene Mutation |
Fujian Cancer Hospital |
2016-07 | PHASE3 |
| NCT03950674 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Merck Sharp & Dohme LLC |
2016-02-22 | PHASE3 |
| NCT03256721 | TERMINATED | Nonsmall Cell Lung Cancer |
Fuzhou General Hospital |
2017-08-16 | PHASE2 |
| NCT02531854 | WITHDRAWN | Carcinoma, Non-Small-Cell Lung |
Advaxis, Inc. |
2018-12 | PHASE2 |
| NCT03432598 | COMPLETED | Locally Advanced Lung Cancer; Metastatic Lung Cancer |
BeiGene |
2017-08-24 | PHASE2 |
| NCT03085914 | COMPLETED | Solid Tumor |
Incyte Corporation |
2017-05-02 | PHASE1; PHASE2 |
| NCT03151161 | UNKNOWN | Lung, Carcinoma |
Sun Yat-sen University |
2015-12 | PHASE2 |
| NCT02117167 | COMPLETED | Non-small Cell Lung Cancer Metastatic |
UNICANCER |
2014-04-23 | PHASE2 |
| NCT03061058 | UNKNOWN | Stomach Neoplasms; Chemotherapy Effect; Chemotherapeutic Toxicity |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2013-04-01 | PHASE3 |
| NCT02357147 | TERMINATED | Mesothelioma, Malignant |
Morphotek |
2015-11-03 | PHASE2 |
| NCT02453282 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Carcinoma NSCLC |
AstraZeneca |
2015-07-21 | PHASE3 |
| NCT02220894 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2014-10-30 | PHASE3 |
| NCT03850444 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2016-08-01 | PHASE3 |
| NCT02296671 | WITHDRAWN | Esophagogastric Cancer |
Washington University School of Medicine |
2015-02 | PHASE2 |
| NCT02029690 | TERMINATED | Pleural Mesothelioma Malignant Advanced; Peritoneal Mesothelioma Malignant Advanced; Non-squamous Non-small Cell Lung Carcinoma; Uveal Melanoma; Hepatocellular Carcinoma; Glioma; Sarcomatoid Carcinoma |
Polaris Group |
2014-04-23 | PHASE1 |
| NCT02723578 | COMPLETED | Metastatic Colorectal Cancer |
Yonsei University |
2015-12-01 | PHASE2 |
| NCT02274038 | TERMINATED | Non-small Cell Lung Cancer; Starting Pemetrexed Based Therapy; Unresectable Cancer |
University of Pennsylvania |
2015-03 | |
| NCT02079636 | COMPLETED | Carcinoma, Non-small Cell Lung |
Eli Lilly and Company |
2014-03-28 | PHASE1 |
| NCT02397928 | COMPLETED | Malignant Pleural Mesothelioma |
NovoCure Ltd. |
2015-02 | PHASE2 |
| NCT02322281 | TERMINATED | Non-small Cell Lung Cancer |
Clovis Oncology, Inc. |
2015-02 | PHASE3 |
| NCT01376310 | TERMINATED | Cancer |
Novartis Pharmaceuticals |
2010-11-02 | PHASE2 |
| NCT02399566 | UNKNOWN | Lung Adenocarcinoma |
Hunan Province Tumor Hospital |
2015-05 | PHASE4 |
| NCT02980991 | COMPLETED | Lung Adenocarcinoma |
Fudan University |
2015-12 | PHASE2 |
| NCT02804646 | UNKNOWN | Adenocarcinoma of Lung |
Anhui Provincial Hospital |
2016-06 | PHASE4 |
| NCT02578680 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Merck Sharp & Dohme LLC |
2016-01-15 | PHASE3 |
| NCT02974933 | UNKNOWN | Nonsmall Cell Lung Cancer |
Wuling Ou |
2016-11 | PHASE2 |
| NCT01868022 | COMPLETED | Neoplasms |
GlaxoSmithKline |
2013-10-09 | PHASE1 |
| NCT01958372 | COMPLETED | Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
2014-08 | PHASE1 |
| NCT02868892 | TERMINATED | Adenocarcinoma of the Cervix; Adenosquamous Cell Carcinoma of the Cervix |
Western Regional Medical Center |
2015-07 | PHASE2 |
| NCT02259582 | COMPLETED | Nonsquamous Nonsmall Cell Neoplasm of Lung |
OncoMed Pharmaceuticals, Inc. |
2015-02 | PHASE2 |
| NCT02607423 | WITHDRAWN | Stage IIIA Non-Small Cell Lung Cancer |
ECOG-ACRIN Cancer Research Group |
2015-11-19 | PHASE2 |
| NCT01041781 | TERMINATED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2010-02 | PHASE3 |
| NCT02669719 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Chest Hospital |
2016-01 | PHASE2 |
| NCT02900742 | COMPLETED | Cancer |
Shanghai University of Traditional Chinese Medicine |
2013-03 | PHASE3 |
| NCT02013453 | WITHDRAWN | Cancer of Head and Neck |
University of Michigan Rogel Cancer Center |
2013-12 | PHASE2 |
| NCT02039674 | COMPLETED | Non-small Cell Lung Carcinoma |
Merck Sharp & Dohme LLC |
2014-02-21 | PHASE1; PHASE2 |
| NCT00741221 | COMPLETED | Non-small-cell Lung Cancer |
Hellenic Oncology Research Group |
2008-06 | PHASE2 |
| NCT02284490 | UNKNOWN | Brain Metastases |
Rongjie Tao |
2014-11 | PHASE2 |
| NCT01719536 | COMPLETED | NSCLC |
Betta Pharmaceuticals Co., Ltd. |
2012-12 | PHASE3 |
| NCT01189968 | COMPLETED | Non Small Cell Lung Cancer |
OncoMed Pharmaceuticals, Inc. |
2010-09 | PHASE1 |
| NCT01723800 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
City of Hope Medical Center |
2013-07 | PHASE1 |
| NCT00614822 | COMPLETED | Non Small Cell Lung Cancer |
Christiana Care Health Services |
2007-11 | PHASE2 |
| NCT00390000 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
Mayo Clinic |
2007-01-25 | PHASE1 |
| NCT01395758 | COMPLETED | Metastatic Non-Small Cell Lung Cancer |
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
2011-07 | PHASE2 |
| NCT01828099 | COMPLETED | Non-Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2013-07-09 | PHASE3 |
| NCT01063283 | COMPLETED | Advanced Non-squamous Non-Small Cell Lung Cancer |
University of Chicago |
2010-03 | |
| NCT02276560 | TERMINATED | Stage IIIA Non-Small Cell Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2015-01 | PHASE2 |
| NCT01774578 | TERMINATED | Non-small Cell Lung Cancer; Progression of Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent |
NewLink Genetics Corporation |
2013-02 | PHASE2; PHASE3 |
| NCT02093962 | TERMINATED | Non-small Cell Lung Cancer |
ImmunoGenesis |
2014-06 | PHASE2 |
| NCT01496742 | COMPLETED | Non-Squamous Non-Small Cell Lung Cancer |
Genentech, Inc. |
2012-04 | PHASE2 |
| NCT00324805 | COMPLETED | Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2007-07-19 | PHASE3 |
| NCT00996567 | COMPLETED | Cancer |
University Hospital, Ghent |
2009-10 | PHASE2 |
| NCT02083679 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
EMD Serono |
2014-07 | PHASE1 |
| NCT00906282 | COMPLETED | Non Small Cell Lung Cancer |
SCRI Development Innovations, LLC |
2009-06 | PHASE2 |
| NCT01443078 | COMPLETED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2011-10 | PHASE2 |
| NCT01836341 | WITHDRAWN | Non-small Cell Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2013-04 | PHASE1 |
| NCT01928160 | WITHDRAWN | Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2014-06 | PHASE2 |
| NCT02148380 | COMPLETED | Non-Small-Cell Lung Cancer |
Baohui Han |
2014-05 | |
| NCT01204307 | COMPLETED | Advanced Non-Squamous Non-Small Cell Lung Cancer |
Chang Gung Memorial Hospital |
2010-01 | PHASE2 |
| NCT01593293 | UNKNOWN | Non-small Cell Lung Cancer |
Asan Medical Center |
2012-03 | PHASE3 |
| NCT01397305 | COMPLETED | Rectal Cancer |
Isofol Medical AB |
2011-04-14 | PHASE1; PHASE2 |
| NCT01700400 | COMPLETED | Non Small Cell Lung Cancer |
Cancer Research and Biostatistics Clinical Trials Consortium |
2012-09 | PHASE1 |
| NCT00470548 | TERMINATED | Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
University of California, Davis |
2007-04 | PHASE1; PHASE2 |
| NCT00703976 | COMPLETED | Cancer |
University of Pittsburgh |
2008-10 | PHASE2 |
| NCT01860040 | TERMINATED | Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer; Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer |
Western Regional Medical Center |
2013-04 | PHASE2 |
| NCT01502202 | UNKNOWN | Non Small Cell Lung Cancer; Adenocarcinoma |
National Cancer Center, Korea |
2012-03 | PHASE2 |
| NCT01116219 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2010-06 | PHASE2 |
| NCT01172028 | COMPLETED | Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer |
University of Arizona |
2005-09 | PHASE1 |
| NCT01783834 | COMPLETED | Previous Treated Metastatic Non-small Cell Lung Cancer |
Gachon University Gil Medical Center |
2008-02 | PHASE2 |
| NCT01544179 | COMPLETED | Non-Small Cell Lung Cancer |
AstraZeneca |
2012-03-15 | PHASE3 |
| NCT00754364 | TERMINATED | NSCLC |
Armando Santoro, MD |
2008-10 | PHASE2 |
| NCT00807573 | COMPLETED | Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2008-12 | PHASE2 |
| NCT00334594 | COMPLETED | Malignant Mesothelioma |
Swiss Cancer Institute |
2005-11-14 | PHASE2 |
| NCT01769066 | COMPLETED | NSCLC |
Fudan University |
2009-12 | PHASE2; PHASE3 |
| NCT01860508 | UNKNOWN | Non-small Cell Lung Cancer |
Fudan University |
2013-02 | |
| NCT01102231 | COMPLETED | Stage III Non-small Cell Lung Cancer |
Intergroupe Francophone de Cancerologie Thoracique |
2010-03 | PHASE2 |
| NCT01490437 | COMPLETED | Urothelial Carcinoma |
Asan Medical Center |
2008-07 | PHASE2 |
| NCT01209520 | COMPLETED | Lung Cancer; Non Small Cell Lung Carcinoma; Hypermethylation |
University of Miami |
2009-07 | |
| NCT01447225 | COMPLETED | Solid Tumors |
Merrimack Pharmaceuticals |
2011-10 | PHASE1 |
| NCT01192165 | COMPLETED | Cancer |
GlaxoSmithKline |
2010-09-14 | PHASE1 |
| NCT01087970 | COMPLETED | Head and Neck Neoplasms |
Eli Lilly and Company |
2010-08 | PHASE2 |
| NCT00942825 | COMPLETED | Metastatic Non-squamous Non Small Cell Lung Cancer |
CanBas Co. Ltd. |
2009-04 | PHASE2 |
| NCT00743379 | COMPLETED | Non-Small Cell Lung Cancer; Prostate Cancer; Pancreatic Cancer |
Threshold Pharmaceuticals |
2008-08 | PHASE1; PHASE2 |
| NCT00940069 | COMPLETED | Non-small-cell Lung Cancer; Adenocarcinoma |
Hunan Province Tumor Hospital |
2009-03 | PHASE2 |
| NCT01579630 | UNKNOWN | NSCLC |
Taipei Veterans General Hospital, Taiwan |
2011-03 | PHASE2; PHASE3 |
| NCT00923273 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
National Cancer Institute (NCI) |
2008-02-29 | PHASE1; PHASE2 |
| NCT00438204 | TERMINATED | Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
2006-05 | PHASE2 |
| NCT00948675 | COMPLETED | Advanced Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2009-09-01 | PHASE3 |
| NCT00921310 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Washington University School of Medicine |
2009-09 | PHASE1; PHASE2 |
| NCT00769600 | TERMINATED | Recurrent Non Small Cell Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2008-11 | PHASE2 |
| NCT01088620 | SUSPENDED | Carcinoma, Non-Small-Cell Lung |
WiSP Wissenschaftlicher Service Pharma GmbH |
2010-04 | PHASE2 |
| NCT01126736 | COMPLETED | Non Small Cell Lung Cancer |
Eisai Inc. |
2010-06-10 | PHASE1; PHASE2 |
| NCT01531790 | COMPLETED | Non-Small Cell Lung Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2011-09 | PHASE1 |
| NCT01211275 | COMPLETED | Malignant Pleural Mesothelioma |
The Netherlands Cancer Institute |
2009-05-22 | PHASE1; PHASE2 |
| NCT01004250 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2009-10 | PHASE2 |
| NCT01005680 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2009-11 | PHASE3 |
| NCT00895648 | TERMINATED | Mesothelioma; Pleural Mesothelioma |
University Health Network, Toronto |
2009-01 | PHASE2 |
| NCT00301808 | COMPLETED | Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
2005-11 | PHASE2 |
| NCT01185847 | COMPLETED | Non-Squamous Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2010-11 | PHASE2 |
| NCT01313663 | TERMINATED | Lung Cancer, Small Cell |
GlaxoSmithKline |
2011-02 | PHASE2 |
| NCT01143974 | COMPLETED | Locally Advanced Malignant Neoplasm |
Chinese Academy of Medical Sciences |
2010-06 | PHASE4 |
| NCT00556322 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2006-03 | PHASE3 |
| NCT01187615 | TERMINATED | Small Cell Lung Carcinoma |
Bayer |
2010-08 | PHASE1 |
| NCT01565538 | COMPLETED | Lung Cancer |
Si-Yu Wang |
2008-12 | PHASE2 |
| NCT00762034 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2008-12 | PHASE3 |
| NCT00702299 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer |
University of Arizona |
2007-09 | PHASE1 |
| NCT00550173 | COMPLETED | Non-Small-Cell Lung Cancer |
Eli Lilly and Company |
2007-11 | PHASE2 |
| NCT00545948 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Duke University |
2007-12 | PHASE2 |
| NCT00577707 | COMPLETED | Non Small Cell Lung Cancer; Lung Cancer |
Memorial Sloan Kettering Cancer Center |
2007-11 | PHASE2 |
| NCT01192230 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Fudan University |
2009-06 | PHASE2 |
| NCT00482014 | COMPLETED | Non-Small-Cell Lung Cancer |
Eli Lilly and Company |
2007-05 | PHASE1; PHASE2 |
| NCT00507858 | COMPLETED | Head and Neck Cancer |
M.D. Anderson Cancer Center |
2005-09 | PHASE1 |
| NCT01109615 | TERMINATED | Metastatic Colorectal Cancer |
Vejle Hospital |
2010-04 | PHASE2 |
| NCT00265785 | TERMINATED | Lung Cancer |
SWOG Cancer Research Network |
2006-07 | PHASE2 |
| NCT00749346 | COMPLETED | Non-small Cell Lung Cancer; NSCLC |
NovoCure Ltd. |
2008-05 | PHASE1; PHASE2 |
| NCT00794417 | TERMINATED | Advanced Carcinoma; Non-small Cell Lung Cancer |
Regeneron Pharmaceuticals |
2008-11-30 | PHASE1; PHASE2 |
| NCT00806819 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2008-12 | PHASE3 |
| NCT00961415 | COMPLETED | Non-Squamous Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2009-08 | PHASE3 |
| NCT01105390 | WITHDRAWN | Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma |
National Cancer Institute (NCI) |
2010-04 | PHASE2 |
| NCT00248495 | COMPLETED | Lung Cancer |
Roswell Park Cancer Institute |
2005-06-08 | PHASE2 |
| NCT00517595 | COMPLETED | Non-Small Cell Lung Cancer |
Accelerated Community Oncology Research Network |
2007-08 | PHASE2 |
| NCT00871403 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2009-07 | PHASE2 |
| NCT00768755 | COMPLETED | Carcinoma, Non-Small Cell Lung |
Pfizer |
2009-01 | PHASE1; PHASE2 |
| NCT00799240 | COMPLETED | Non Small Cell Lung Cancer |
University of Kansas |
2009-06 | PHASE2 |
| NCT00434174 | COMPLETED | Non Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2006-12 | PHASE1 |
| NCT00606021 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2008-01 | PHASE2 |
| NCT01194453 | COMPLETED | Non-small Cell Lung Cancer; Efficacy |
Sun Yat-sen University |
2009-11 | PHASE2 |
| NCT00589667 | COMPLETED | Head and Neck Cancer |
Memorial Sloan Kettering Cancer Center |
2006-09 | PHASE2 |
| NCT00520676 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2007-10 | PHASE3 |
| NCT00789373 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2008-11 | PHASE3 |
| NCT00295503 | COMPLETED | Mesothelioma |
University of Texas Southwestern Medical Center |
2006-02 | PHASE2 |
| NCT02182102 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Boehringer Ingelheim |
2005-09 | PHASE1 |
| NCT00528619 | COMPLETED | Neoplasms |
Pfizer |
2006-11 | PHASE1 |
| NCT00440414 | COMPLETED | Non Small Cell Lung Cancer |
Hellenic Oncology Research Group |
2006-04 | PHASE3 |
| NCT00903292 | UNKNOWN | Non-Small Cell Lung Cancer |
National Cheng-Kung University Hospital |
2009-03 | |
| NCT00415636 | COMPLETED | Cancer |
Eli Lilly and Company |
2007-01 | PHASE1 |
| NCT00614965 | COMPLETED | Non Small Cell Lung Cancer |
Hellenic Oncology Research Group |
2006-11 | PHASE2 |
| NCT00415194 | COMPLETED | Head and Neck Neoplasms |
Eli Lilly and Company |
2006-12 | PHASE3 |
| NCT00227539 | COMPLETED | Lung Cancer |
University of Washington |
2005-07 | PHASE2 |
| NCT00489359 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer |
Eli Lilly and Company |
2005-07 | PHASE1; PHASE2 |
| NCT00712062 | WITHDRAWN | Primary Central Nervous System Lymphoma |
University of Florida |
2009-02 | PHASE2 |
| NCT00456261 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2007-03 | PHASE2 |
| NCT00520936 | COMPLETED | Osteosarcoma; Medulloblastoma; Sarcoma, Ewing's; Neuroblastoma (Measurable Disease); Neuroblastoma (Metaiodobenzylguanidine; Positive Evaluable); Rhabdomyosarcoma; Ependymoma; Non-brainstem High-grade Glioma |
Eli Lilly and Company |
2007-09 | PHASE2 |
| NCT00745875 | COMPLETED | Non Small Cell Lung Cancer; Lung Cancer |
AstraZeneca |
2008-08 | PHASE2 |
| NCT00424242 | COMPLETED | Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis; Unspecified Adult Solid Tumor, Protocol Specific |
Northwestern University |
2007-01 | EARLY_PHASE1 |
| NCT00732992 | COMPLETED | Neoplasm, Malignant |
Pfizer |
2008-08 | PHASE1 |
| NCT00487669 | COMPLETED | Advanced Non-small Cell Lung Cancer |
Dartmouth-Hitchcock Medical Center |
2006-10 | PHASE2 |
| NCT00383266 | TERMINATED | Esophageal Neoplasms |
Washington University School of Medicine |
2006-10 | PHASE2 |
| NCT01442909 | COMPLETED | Non-small-cell Lung Cancer |
Taipei Veterans General Hospital, Taiwan |
2008-03 | PHASE4 |
| NCT00101283 | COMPLETED | Mesothelioma |
Eastern Cooperative Oncology Group |
2006-02-23 | PHASE2 |
| NCT00308750 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2006-03 | PHASE2 |
| NCT00528281 | COMPLETED | Lung Cancer, Non-Small Cell |
GlaxoSmithKline |
2007-09-20 | PHASE1 |
| NCT00733031 | TERMINATED | Cancer,; Solid Tumors; Advanced Solid Malignancies |
AstraZeneca |
2008-08 | PHASE1 |
| NCT00533429 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2007-10 | PHASE2 |
| NCT00226577 | COMPLETED | Lung Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2004-02 | PHASE2 |
| NCT00427466 | COMPLETED | Sarcoma |
University Hospital Tuebingen |
2007-01 | PHASE2 |
| NCT00350792 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2006-08 | PHASE2 |
| NCT00320073 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
UNC Lineberger Comprehensive Cancer Center |
2006-08 | PHASE1 |
| NCT00530621 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2007-09 | PHASE2 |
| NCT01004601 | COMPLETED | Non Small Cell Lung Cancer |
Chang Gung Memorial Hospital |
2005-03 | |
| NCT00380718 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2006-11 | PHASE4 |
| NCT00351039 | TERMINATED | Non-Small Cell Lung Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2006-07 | PHASE1; PHASE2 |
| NCT00370292 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2006-09 | PHASE2 |
| NCT00473486 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
University Hospital Muenster |
2007-05 | PHASE1; PHASE2 |
| NCT00394147 | TERMINATED | Head and Neck Cancer |
Fox Chase Cancer Center |
2006-10 | PHASE2 |
| NCT00191308 | COMPLETED | Non-Small Cell Lung Cancer; Carcinoma |
Eli Lilly and Company |
2005-05 | PHASE2 |
| NCT00330915 | COMPLETED | Rectal Neoplasms |
Eli Lilly and Company |
2006-06 | PHASE2 |
| NCT00315861 | COMPLETED | Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Lung Cancer |
SCRI Development Innovations, LLC |
2006-03 | PHASE1 |
| NCT00293579 | COMPLETED | Head and Neck Cancer |
Ohio State University Comprehensive Cancer Center |
2006-02 | PHASE2 |
| NCT00190671 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2005-06 | PHASE1; PHASE2 |
| NCT00149214 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2005-09 | PHASE2 |
| NCT00383331 | TERMINATED | Non-Small-Cell Lung Cancer |
Eli Lilly and Company |
2007-02 | PHASE2 |
| NCT00321308 | TERMINATED | Carcinoma, Non-Small Cell Lung |
Pfizer |
2006-09 | PHASE2 |
| NCT00063570 | COMPLETED | Breast Cancer; Breast Neoplasms |
Eli Lilly and Company |
2003-07 | PHASE2 |
| NCT00268437 | TERMINATED | Esophageal Cancer |
Alliance for Clinical Trials in Oncology |
2006-04 | PHASE2 |
| NCT00259285 | TERMINATED | Non-Small-Cell Lung Cancer |
Eli Lilly and Company |
2005-11 | PHASE2 |
| NCT00106626 | COMPLETED | Advanced Cancer |
Merck Sharp & Dohme LLC |
2005-08 | PHASE1 |
| NCT00106002 | COMPLETED | Breast Cancer; Breast Neoplasms, Male; Carcinoma, Ductal |
Eli Lilly and Company |
2005-04 | PHASE2 |
| NCT00502567 | COMPLETED | Advanced Solid Tumor |
AstraZeneca |
2005-01 | PHASE1 |
| NCT00387322 | COMPLETED | Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
University of California, Davis |
2005-03 | PHASE1; PHASE2 |
| NCT00377520 | COMPLETED | Neoplasms; Neoplasms by Site; Urogenital Neoplasms; Genital Neoplasms, Female; Uterine Neoplasms; Endometrial Neoplasms; Cancer of Endometrium; Endometrial Cancer; Cancer of the Endometrium; Endometrium Cancer; Neoplasms, Endometrial |
Eli Lilly and Company |
2006-09 | PHASE2 |
| NCT00190983 | COMPLETED | Cervical Intraepithelial Neoplasia; Uterine Neoplasms; Genital Neoplasms, Female |
Eli Lilly and Company |
2005-02 | PHASE2 |
| NCT00096187 | TERMINATED | Gestational Trophoblastic Tumor |
Gynecologic Oncology Group |
2005-07 | PHASE2 |
| NCT00230542 | COMPLETED | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer |
Dana-Farber Cancer Institute |
2005-09 | PHASE2 |
| NCT01172470 | COMPLETED | Head and Neck Cancer |
University of Chicago |
2005-06 | PHASE2 |
| NCT00107419 | COMPLETED | Sarcoma |
SWOG Cancer Research Network |
2005-09 | PHASE2 |
| NCT00470405 | COMPLETED | Lymphoma; Solid Tumor |
Vanderbilt-Ingram Cancer Center |
2004-05 | PHASE1 |
| NCT00087711 | COMPLETED | Non Small Cell Lung Carcinoma |
Eli Lilly and Company |
2004-07 | PHASE3 |
| NCT00198133 | COMPLETED | Thymoma; Thymic Carcinoma |
Patrick Joseph Loehrer Sr. |
2005-01 | PHASE2 |
| NCT00389805 | COMPLETED | Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
University of California, Davis |
2005-03 | PHASE1; PHASE2 |
| NCT00087087 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
2004-07 | PHASE2 |
| NCT00078260 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2003-12 | PHASE3 |
| NCT00087113 | COMPLETED | Cervical Cancer |
Gynecologic Oncology Group |
2004-08 | PHASE2 |
| NCT00506051 | COMPLETED | Carcinoma; Non-Small Cell Lung; Lung Cancer |
Genzyme, a Sanofi Company |
2005-07 | PHASE1 |
| NCT00070473 | COMPLETED | Unspecified Childhood Solid Tumor, Protocol Specific |
Children's Oncology Group |
2003-10 | PHASE1 |
| NCT00216216 | TERMINATED | Small Cell Lung Cancer |
Hoosier Cancer Research Network |
2005-01 | PHASE2 |
| NCT00022646 | COMPLETED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2001-08 | PHASE2 |
| NCT00095225 | COMPLETED | Non-Small-Cell Lung Carcinoma; Neoplasm Recurrence, Local |
Genentech, Inc. |
2004-07 | PHASE2 |
| NCT00055432 | TERMINATED | Ovarian Cancer; Peritoneal Cancer |
Eli Lilly and Company |
PHASE2 | |
| NCT00989690 | UNKNOWN | Lung Cancer |
Istituto Scientifico H. San Raffaele |
2008-02 | PHASE3 |
| NCT00191347 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-10 | PHASE2 |
| NCT00744900 | COMPLETED | Lung Cancer |
University Hospital, Brest |
2008-09 | PHASE2 |
| NCT00386815 | COMPLETED | Malignant Pleural Mesothelioma |
Eli Lilly and Company |
2006-10 | PHASE2 |
| NCT00079872 | COMPLETED | Colorectal Cancer |
Eli Lilly and Company |
2004-02 | PHASE2 |
| NCT00034606 | COMPLETED | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms |
Eli Lilly and Company |
PHASE2 | |
| NCT00035061 | COMPLETED | Urologic Neoplasms; Metastases, Neoplasm |
Eli Lilly and Company |
PHASE2 | |
| NCT00190840 | COMPLETED | Carcinoma, Non-Small Cell Lung |
Eli Lilly and Company |
2003-09 | PHASE2 |
| NCT00061464 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Eli Lilly and Company |
2003-02 | PHASE2 |
| NCT00290017 | TERMINATED | Carcinoma, Non-Small-Cell Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary |
Point Therapeutics |
2006-02 | PHASE3 |
| NCT00034502 | COMPLETED | Colorectal Cancer |
Eli Lilly and Company |
PHASE1; PHASE2 | |
| NCT00034619 | COMPLETED | Colorectal Cancer |
Eli Lilly and Company |
PHASE2 | |
| NCT00192088 | COMPLETED | Advanced Gastric Carcinoma |
Eli Lilly and Company |
2004-05 | PHASE2 |
| NCT00191750 | COMPLETED | Carcinoma, Small Cell |
Eli Lilly and Company |
2004-07 | PHASE2 |
| NCT00061477 | COMPLETED | Mesothelioma |
Eli Lilly and Company |
2002-12 | PHASE2 |
| NCT00191412 | COMPLETED | Liver Cancer |
Eli Lilly and Company |
2005-01 | PHASE2 |
| NCT00061451 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Eli Lilly and Company |
2002-12 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-04)
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Pemetrexed Disodium (LY231514) Solubility in DMSO
- Pemetrexed Disodium (LY231514) Stock Solution
- Pemetrexed Disodium (LY231514) Storage
- Pemetrexed Disodium (LY231514) Stability
- Pemetrexed Disodium (LY231514) Molecular Weight
- Pemetrexed Disodium (LY231514) SMILES
- Pemetrexed Disodium (LY231514) CAS Number
- Pemetrexed Disodium (LY231514) Chemical Structure (2D and 3D)
- Pemetrexed Disodium (LY231514) SDS|MSDS